Ellsworth Advisors’s Integra LifeSciences IART Stock Holding History

Ellsworth Advisors’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-119,668	Closed	-$3.49M	–	187
2024 Q2	$3.49M	Buy	119,668 +7,773	+7%	+$231K	0.97%	45
2024 Q1	$3.67M	Buy	111,895 +5,283	+5%	+$211K	1.05%	44
2023 Q4	$4.64M	Buy	106,612 +4,112	+4%	+$162K	1.47%	18
2023 Q3	$3.88M	Buy	+102,500	New	+$4.31M	1.38%	29

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SHCM

Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ellsworth Advisors's IART Position: Q3 2024 in Review

Ellsworth Advisors sold out of Integra LifeSciences (IART) in Q3 2024, closing a stake of 119,668 shares — an estimated $3.49M sold.

Ellsworth Advisors first reported a position in IART in Q3 2023 and held it in 4 quarters. The position peaked at $4.64M in Q4 2023. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

Ellsworth Advisors reported no remaining Integra LifeSciences position as of Q3 2024 after selling out during the quarter.
Ellsworth Advisors sold 119,668 Integra LifeSciences shares in Q3 2024, an estimated $3.49M.
Ellsworth Advisors first reported a position in Integra LifeSciences in Q3 2023 and held it in 4 quarters.
Ellsworth Advisors's Integra LifeSciences position peaked at $4.64M in Q4 2023.
225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on Ellsworth Advisors's 13F filing for Q3 2024, filed 16 Oct 2024.